## Thenappan Chandrasekar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3436088/publications.pdf

Version: 2024-02-01

114 papers 1,649 citations

361045 20 h-index 37 g-index

115 all docs

115 does citations

115 times ranked 3217 citing authors

#	Article	IF	CITATIONS
1	Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Translational Andrology and Urology, 2015, 4, 365-80.	0.6	310
2	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
3	Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naìve Prostate Cancer: A Systematic Review and Network Meta-analysis. European Urology, 2018, 73, 834-844.	0.9	86
4	Metastatic renal cell carcinoma: Patterns and predictors of metastases—A contemporary population-based series. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 661.e7-661.e14.	0.8	76
5	Natural History of Complex Renal Cysts: Clinical Evidence Supporting Active Surveillance. Journal of Urology, 2018, 199, 633-640.	0.2	57
6	Targeting molecular resistance in castration-resistant prostate cancer. BMC Medicine, 2015, 13, 206.	2.3	52
7	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology, 2018, 74, 309-321.	0.9	51
8	Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. European Urology, 2021, 80, 575-588.	0.9	48
9	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naà ve Men: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 203, 1085-1093.	0.2	44
10	Cancer diagnosis and risk of suicide after accounting for prediagnosis psychiatric care: A matchedâ€cohort study of patients with incident solidâ€organ malignancies. Cancer, 2019, 125, 2886-2895.	2.0	43
11	The impact of psychiatric utilisation prior to cancer diagnosis on survival of solid organ malignancies. British Journal of Cancer, 2019, 120, 840-847.	2.9	41
12	Twitter and academic Urology in the United States and Canada: a comprehensive assessment of the Twitterverse in 2019. BJU International, 2020, 125, 173-181.	1.3	35
13	A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 343-350.	0.9	33
14	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. Journal of Urology, 2015, 194, 304-309.	0.2	28
15	Changing Trends for Suicidal Death in Patients With Bladder Cancer: A 40+ Year Population-level Analysis. Clinical Genitourinary Cancer, 2018, 16, 206-212.e1.	0.9	28
16	The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entity. Cancer, 2019, 125, 1050-1059.	2.0	28
17	Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. Journal of Urology, 2015, 193, 436-442.	0.2	27
18	Comparison of lymph node yield in robotâ€assisted laparoscopic prostatectomy with that in open radical retropubic prostatectomy. BJU International, 2011, 107, 1136-1140.	1.3	25

#	Article	IF	Citations
19	The effect of BMI on clinicopathologic and functional outcomes after open radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 297-302.	0.8	25
20	Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. European Urology Oncology, 2018, 1, 238-241.	2.6	25
21	Association of Race With Cancer-Related Financial Toxicity. JCO Oncology Practice, 2022, 18, e271-e283.	1.4	23
22	Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines. Journal of Urology, 2018, 199, 906-914.	0.2	22
23	Autophagy and urothelial carcinoma of the bladder: A review. Investigative and Clinical Urology, 2016, 57, S89.	1.0	19
24	Germ Cell Testicular Tumorsâ€"Contemporary Diagnosis, Staging and Management of Localized and Advanced disease. Urology, 2019, 125, 8-19.	0.5	19
25	Stress Urinary Incontinence post-Holmium Laser Enucleation of the Prostate: a Single-Surgeon Experience. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 624-631.	0.7	18
26	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Urologic Oncology: Seminars and Original Investigations, 2018, 36, 79.e11-79.e17.	0.8	14
27	Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men. European Urology Oncology, 2020, 3, 291-297.	2.6	14
28	Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 603.e17-603.e25.	0.8	14
29	Urinary Diversion during and after Pediatric Pyeloplasty: A Population Based Analysis of More than 2,000 Patients. Journal of Urology, 2014, 192, 214-220.	0.2	12
30	The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer. European Urology Focus, 2021, 7, 537-545.	1.6	12
31	Radical prostatectomy in patients aged 75 years or older: review of the literature. Asian Journal of Andrology, 2019, 21, 32.	0.8	12
32	Twitter Engagement of Medical Students Applying to Urology Residency During COVID-19: A Mixed Methods Study. Urology, 2022, 165, 120-127.	0.5	12
33	Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. Canadian Urological Association Journal, 2020, 14, E453-E457.	0.3	11
34	Postoperative auras and the risk of recurrent seizures. Epilepsy Research, 2008, 78, 195-200.	0.8	10
35	Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. Oncotarget, 2018, 9, 18797-18810.	0.8	10
36	Molecular Characterization of Bladder Cancer. Current Urology Reports, 2018, 19, 107.	1.0	10

#	Article	IF	Citations
37	Lynch Syndrome in Urologic Malignancies – What Does the Urologist Need to Know?. Urology, 2019, 134, 24-31.	0.5	10
38	Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma. World Journal of Urology, 2020, 38, 2547-2554.	1.2	10
39	Internet-Based Patient Survey on Urolithiasis Treatment and Patient Satisfaction. Journal of Endourology, 2015, 29, 725-729.	1.1	8
40	Robotic-assisted vs. open radical prostatectomy: an update to the never-ending debate. Translational Andrology and Urology, 2018, 7, S120-S123.	0.6	8
41	High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis. Oncotarget, 2018, 9, 16731-16743.	0.8	8
42	Identification of an Oxygenic Reaction Center psbADC Operon in the Cyanobacterium Gloeobacter violaceus PCC 7421. Molecular Biology and Evolution, 2012, 29, 35-38.	3.5	7
43	Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there aÂMeaningful Impact?. Bladder Cancer, 2016, 2, 441-448.	0.2	7
44	Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives. Canadian Urological Association Journal, 2018, 12, E210-8.	0.3	7
45	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. European Urology Oncology, 2019, 2, 88-96.	2.6	7
46	Poor Adherence to International Cancer Prevention Recommendations Among Patients With Prostate Cancer: First Results From the MARTINI-Lifestyle Cohort. European Urology Focus, 2020, 6, 935-940.	1.6	7
47	Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer. Current Opinion in Urology, 2018, 28, 46-54.	0.9	6
48	Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces. Canadian Urological Association Journal, 2018, 12, 328-336.	0.3	6
49	Impact of Tumor Regional Involvement on Active Surveillance Outcomes: Validation of the Cumulative Cancer Location Metric in a US Population. European Urology Focus, 2020, 6, 235-241.	1.6	6
50	The deleterious association between proton pump inhibitors and prostate cancer-specific mortality $\hat{a} \in \hat{a}$ a population-based cohort study. Prostate Cancer and Prostatic Diseases, 2020, 23, 622-629.	2.0	6
51	Prostatic Stromal Tumors of Uncertain Malignant Potential. Urology, 2019, 132, e3-e4.	0.5	5
52	Age Differences in Patient-reported Psychological and Physical Distress Symptoms in Bladder Cancer Patients – A Cross Sectional Study. Urology, 2019, 134, 154-162.	0.5	5
53	Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs. JCO Precision Oncology, 2021, 5, 1377-1386.	1.5	5
54	Circulating Vitamin D and Selenium Levels and Outcome in Prostate Cancer Patients: Lessons from the MARTINI-Lifestyle Cohort. European Urology Focus, 2021, 7, 973-979.	1.6	5

#	Article	IF	CITATIONS
55	MRI as a screening tool for prostate cancer: current evidence and future challenges. World Journal of Urology, 2023, 41, 921-928.	1.2	5
56	Setting the Standards: Examining Research Productivity Among Academic Urologists in the USA and Canada in 2019. European Urology Focus, 2021, 7, 489-496.	1.6	4
57	Outcomes of Active Surveillance for Men With Intermediate Risk Prostate Cancer: A Population-Based Analysis. Urology, 2021, 155, 101-109.	0.5	4
58	Lymphadenectomy in Gleason 7 prostate cancer: Adherence to guidelines and effect on clinical outcomes. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 13.e11-13.e18.	0.8	3
59	Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice. Journal of Urology, 2018, 199, 251-256.	0.2	3
60	A novel predictor of clinical progression in patients on active surveillance for prostate cancer. Canadian Urological Association Journal, 2018, 13, 250-255.	0.3	3
61	Is there an association between a history of military service and cancer diagnosis? Results from a US national-level study of self-reported outcomes. Cancer Causes and Control, 2021, 32, 47-55.	0.8	3
62	Salvage radical prostatectomy: a few good men. BJU International, 2016, 117, 9-10.	1.3	2
63	Case â€' Foamy high-grade prostatic intraepithelial neoplasia: A false positive for prostate cancer on multiparametric magnetic resonance imaging?. Canadian Urological Association Journal, 2018, 12, E256-9.	0.3	2
64	The association between physician trust and prostate-specific antigen screening: Implications for shared decision-making. Canadian Urological Association Journal, 2018, 12, .	0.3	2
65	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. Journal of Urology, 2018, 200, 1056-1061.	0.2	2
66	Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Coreâ€in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis. Urology, 2020, 137, 102-107.	0.5	2
67	Stakeholder Perspective on Opioid Stewardship After Prostatectomy: Evaluating Barriers and Facilitators From the Pennsylvania Urology Regional Collaborative. Urology, 2020, 145, 120-126.	0.5	2
68	Predictors of prostateâ€specific antigen testing in men aged ≥55Âyears: A crossâ€sectional study based on patientâ€reported outcomes. International Journal of Urology, 2020, 27, 711-718.	0.5	2
69	Nonobstetrical Robotic-Assisted Laparoscopic Surgery in Pregnancy: A Systematic Literature Review. Urology, 2021, 151, 58-66.	0.5	2
70	Robotic Adrenalectomy for Functional Adenoma in Second Trimester Treats Worsening Hypertension. Urology, 2021, 151, 67-71.	0.5	2
71	Can postâ€treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?. BJU International, 2021, 127, 654-664.	1.3	2
72	Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis Journal of Clinical Oncology, 2020, 38, 131-131.	0.8	2

#	Article	IF	CITATIONS
73	Perioperative Outcomes following Neoadjuvant Chemotherapy and Radical Cystectomy—Is There Room for Improvement?. Urology Practice, 2016, 3, 364-370.	0.2	1
74	Comparing quality of life outcomes after prostate cancer treatment. Nature Reviews Urology, 2017, 14, 396-397.	1.9	1
75	Is 68 Ga-Prostate-specific Membrane Antigen–ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?. European Urology, 2018, 73, 662-663.	0.9	1
76	Two Cases of Arterioureteral Fistula in the Setting of Previous Radiation Therapy and Indwelling Ureteral Stents: Results of Endovascular Management. Clinical Genitourinary Cancer, 2018, 16, e979-e983.	0.9	1
77	The Promise and Disappointment of Neoadjuvant Chemotherapy and Transurethral Resection for Muscle Invasive Bladder Cancer: Updated Results and Long-Term Followup. Urology Practice, 2018, 5, 305-310.	0.2	1
78	Multiparametric <scp>MRI</scp> : an important tool to improve risk stratification for active surveillance in prostate cancer. BJU International, 2018, 122, 721-722.	1.3	1
79	Incorporating mpMRI biopsy data into established pre-RP nomograms: potential impact of an increasingly common clinical scenario. Therapeutic Advances in Urology, 2019, 11, 175628721988280.	0.9	1
80	Parapelvic Dystrophic Calcification as a Result of Mitomycin C Extravasation. Urology, 2020, 136, e34-e36.	0.5	1
81	Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease. European Urology Focus, 2020, 7, 797-806.	1.6	1
82	Prostate-specific Antigen Testing in Men with Disabilities: A Cross-sectional Analysis of the Health Information National Trends Survey. European Urology Focus, 2022, 8, 1125-1132.	1.6	1
83	RNA-sequencing to identify three different molecular grades and immune checkpoint cascades with distinct clinical behaviour in NMIBC Journal of Clinical Oncology, 2018, 36, 412-412.	0.8	1
84	The multidisciplinary clinic approach for bladder cancer treatment in the neoadjuvant therapy era Journal of Clinical Oncology, 2020, 38, 475-475.	0.8	1
85	Active surveillance in intermediate risk prostate cancer. Archivos Espanoles De Urologia, 2019, 72, 157-166.	0.1	1
86	Hospital-specific antibiograms and antibiotic prophylaxis for prostate biopsies: a reexamination of AUA recommendations. Canadian Journal of Urology, 2020, 27, 10099-10104.	0.0	1
87	Simple frameshifts in minimally invasive surgery postoperative pain management significantly reduce opiate prescriptions. Canadian Journal of Urology, 2020, 27, 10250-10256.	0.0	1
88	1946 INVERSE CORRELATION BETWEEN PROSTATE SIZE AND POSITIVE SURGICAL MARGINS IN ROBOT ASSISTED LAPAROSCOPIC PROSTATECTOMY AND RADICAL RETROPUBIC PROSTATECTOMY. Journal of Urology, 2010, 183, .	0.2	0
89	MP18-10 INTERNET-BASED PATIENT SURVEY ON UROLITHIASIS TREATMENT AND PATIENT SATISFACTION. Journal of Urology, 2014, 191, .	0.2	O
90	PD33-05 THE PROMISE AND DISAPPOINTMENT OF SEQUENTIAL THERAPY AFTER NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER: UPDATED RESULTS AND LONG-TERM FOLLOW-UP. Journal of Urology, 2016, 195, .	0.2	0

#	Article	IF	CITATIONS
91	PD11-06 CYSTIC RENAL MASSES: IS THE BOSNIAK CLASSIFICATION SYSTEM AN ADEQUATE PREDICTOR OF SURVIVAL?. Journal of Urology, 2017, 197, .	0.2	O
92	MP64-06 LYMPHADENECTOMY IN GLEASON 7 PROSTATE CANCER: UTILIZATION AND ADHERENCE TO GUIDELINES. Journal of Urology, 2017, 197, .	0.2	O
93	MP14-20 PREDICTORS OF EARLY DISEASE SPECIFIC MORTALITY AMONG PATIENTS WITH PROSTATE ADENOCARCINOMA BONE METASTASIS AT DIAGNOSIS. Journal of Urology, 2017, 197, .	0.2	O
94	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy. JAMA Oncology, 2018, 4, 1620.	3.4	O
95	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. Canadian Urological Association Journal, 2019, 13, E292-E299.	0.3	O
96	Localized Prostate Cancer: Exploring the Boundaries of Current Treatment Paradigms. European Urology Focus, 2020, 6, 199-200.	1.6	O
97	The suggested chemopreventive association of metformin with prostate cancer in diabetic patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 191.e17-191.e24.	0.8	O
98	Genomic analysis for active surveillance to predict upstaging after prostatectomy Journal of Clinical Oncology, 2021, 39, 258-258.	0.8	O
99	The use of 3D printed models on trainee and patient experience for partial nephrectomies Journal of Clinical Oncology, 2021, 39, 363-363.	0.8	O
100	Prostate-specific antigen testing in the disabled population: A cross-sectional analysis of the Health Information National Trends Survey (HINTS) Journal of Clinical Oncology, 2021, 39, e17000-e17000.	0.8	0
101	â€~Case of the Month' from Thomas Jefferson University, Philadelphia, PA, USA: a large renal pseudoaneurysm masquerading as advanced renal cell carcinoma. BJU International, 2021, 128, 158-161.	1.3	O
102	Overview of Prostate Cancer Genetic Testing. Urologic Clinics of North America, 2021, 48, 279-282.	0.8	0
103	AUTHOR REPLY. Urology, 2021, 155, 109.	0.5	O
104	Acute Urinary Retention. , 2014, , 189-193.		0
105	The impact of pre-cancer (Ca) diagnosis (Dx) psychiatric utilization (PU) on survival in patients with solid organ ca: A population analysis in Ontario, Canada Journal of Clinical Oncology, 2018, 36, e22144-e22144.	0.8	O
106	What is the clinical utility of next generation sequencing (NGS) in advanced urologic malignancies?. Journal of Clinical Oncology, 2019, 37, 285-285.	0.8	О
107	Incorporating mpMRI Biopsy data into established pre-RP nomograms: Potential impact of an increasingly common clinical scenario Journal of Clinical Oncology, 2019, 37, 32-32.	0.8	O
108	Questioning the status quo: Should Gleason 3+3=6 PCa be considered a "negative core―for pre-RP risk nomograms?. Journal of Clinical Oncology, 2019, 37, 31-31.	0.8	0

#	Article	IF	CITATIONS
109	Reply by Authors. Journal of Urology, 2020, 203, 1093-1093.	0.2	O
110	Editorial Comment. Journal of Urology, 2020, 204, 301-302.	0.2	0
111	The deleterious association between proton pump inhibitors and prostate cancer specific death Journal of Clinical Oncology, 2020, 38, 309-309.	0.8	O
112	Comparison of prostate specific antigen testing in men aged 55 to 69 with and without a history of cancer Journal of Clinical Oncology, 2022, 40, 230-230.	0.8	0
113	The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy. Canadian Urological Association Journal, 2021, 16, .	0.3	O
114	Exploring the accuracy of multiparametric MRI in prostate cancer staging: An institutional retrospective study Journal of Clinical Oncology, 2022, 40, e17056-e17056.	0.8	O